<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856050</url>
  </required_header>
  <id_info>
    <org_study_id>08-341</org_study_id>
    <nct_id>NCT00856050</nct_id>
  </id_info>
  <brief_title>Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma</brief_title>
  <official_title>Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if letrozole is effective at controlling
      the growth or spread of estrogen and/or progesterone receptor positive uterine
      leiomyosarcoma. This drug has been used in research studies for other cancers and is
      currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone
      levels in the body, it may be helpful to control tumors that express hormone receptors (
      ER/PR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will take letrozole orally once a day. During the research study the
           following tests and procedures will be performed:

        -  Visit 1 (Day 1): physical examination, vital signs and blood work

        -  Visit 2 (Day 43): physical examination, vital signs, blood work, CT or MRI scan

        -  Visit 3 (Day 85): physical examination, vital signs, blood work, CT or MRI scan

        -  Participants will remain on the study drug as long as they do not have any serious sife
           effect and their disease does not get worse
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the Activity of Letrozole in Post Menopausal Women With Advanced Estrogen (ER)/Progesterone (PR)-Positive Uterine Leiomyosarcoma.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The progression free survival rate at 12 weeks was 46% (90%CI, 29%-64%)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm trial - all patients received letrozole 2.5mg by mouth per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Taken orally once a day continuously</description>
    <arm_group_label>letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed, advanced estrogen (ER)/progesterone
             receptor (PR) positive leiomyosarcoma of uterine origin, for which standard
             multi-modality curative therapies do not exist or are no longer effective

          -  Patients must be postmenopausal. Postmenopausal is defined as any of the following:
             1)Bilateral oophorectomy 2) 60 years of age or older 3)Younger than 60 AND
             amenorrheic for 12 months or more AND follicle stimulating hormone (FSH) and
             estradiol (E2) within postmenopausal range 4)Ovarian ablation radiotherapy confirmed
             by FSH and estradiol (E2) level in the postmenopausal range

          -  Evidence of ER and/or PR positivity, either in primary or secondary tumor tissue

          -  Measurable disease outside of a prior irradiated area as defined by RECIST
             guidelines. A lesion in a previously irradiated area is not eligible for measurable
             diseae unless there is objective evidence of progression of the lesion prior to study
             enrollment

          -  18 years of age or older

          -  Life expectancy of 3 months or more

          -  ECOG Performance Status 0, 1, or 2

          -  No limit to number of prior chemotherapies or biologics

          -  Normal organ function as outlined in the protocol

          -  Resolution of clinically significant toxicities related to prior therapies

        Exclusion Criteria:

          -  Pre-menopausal women

          -  Participants who have had systemic anti-cancer therapy within 3 weeks of study entry
             (8 weeks for nitrosoureas or mitomycin C)

          -  Palliative radiotherapy within 2 weeks of study entry

          -  Major surgery within 2 weeks of study entry

          -  Prior hormonal therapy for the treatment of uterine leiomyosarcoma (prior hormone
             replacement therapy is allowed)

          -  Participants may not be receiving any other concomitant investigational agents

          -  Uncontrolled brain or central nervous system metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to letrozole

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Individuals with a history of a different malignancy, other than cervical cancer in
             situ, basal cell or squamous cell carcinoma of the skin, are ineligible, except if
             they have been disease-free for at least 5 years, and are deemed by the investigator
             to be at low risk for recurrence of that malignancy OR other primary malignancy is
             neither currently clinically significant nor requiring active intervention
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2009</firstreceived_date>
  <firstreceived_results_date>January 9, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Suzanne George, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>estrogen receptor positive</keyword>
  <keyword>progesterone receptor positive</keyword>
  <keyword>letrozole</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Letrozole</title>
          <description>Experimental: letrozole single arm trial - all patients received letrozole 2.5mg by mouth per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>27 patients were enrolled, and 26 patients received at least one dose of study medication and were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Letrozole</title>
          <description>letrozole 2.5mg by mouth per day</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56" lower_limit="44" upper_limit="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Activity of Letrozole in Post Menopausal Women With Advanced Estrogen (ER)/Progesterone (PR)-Positive Uterine Leiomyosarcoma.</title>
        <description>The progression free survival rate at 12 weeks was 46% (90%CI, 29%-64%)</description>
        <time_frame>3 years</time_frame>
        <safety_issue>No</safety_issue>
        <population>data below are reported as progression free rate (%)</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>letrozole 2.5mg by mouth per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evaluate the Activity of Letrozole in Post Menopausal Women With Advanced Estrogen (ER)/Progesterone (PR)-Positive Uterine Leiomyosarcoma.</title>
            <description>The progression free survival rate at 12 weeks was 46% (90%CI, 29%-64%)</description>
            <units>percentage of participants progression f</units>
            <param>Number</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46" lower_limit="29" upper_limit="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Letrozole</title>
          <description>Experimental: letrozole single arm trial - all patients received letrozole 2.5mg by mouth per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint= pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle= pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Suzanne George</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-5204</phone>
      <email>sgeorge2@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
